196 related articles for article (PubMed ID: 18566845)
1. Pricing and reimbursement of pharmaceuticals in Italy.
Folino-Gallo P; Montilla S; Bruzzone M; Martini N
Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
[TBL] [Abstract][Full Text] [Related]
2. Pricing and reimbursement of pharmaceuticals in Sweden.
Jönsson B
Pharmacoeconomics; 1994; 6 Suppl 1():51-60. PubMed ID: 10172482
[TBL] [Abstract][Full Text] [Related]
3. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
Pavenik N
Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
[TBL] [Abstract][Full Text] [Related]
4. Reimbursed treatment, regulated in the national frame contract.
Antonova J; Dimitrova Z
Boll Chim Farm; 2001; 140(4):279-82. PubMed ID: 11570227
[TBL] [Abstract][Full Text] [Related]
5. [The Israeli pharmaceutical market].
Shani S; Shemer J
Harefuah; 1999 Jul; 137(1-2):1-4, 88. PubMed ID: 10959264
[TBL] [Abstract][Full Text] [Related]
6. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
7. The pricing and reimbursement of pharmaceuticals.
Towse A
Pharmacoeconomics; 1994; 6 Suppl 1():36-8. PubMed ID: 10155584
[TBL] [Abstract][Full Text] [Related]
8. Pricing and reimbursement of orphan drugs: the need for more transparency.
Simoens S
Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
[TBL] [Abstract][Full Text] [Related]
9. The drug budget silo mentality: the French case.
Le Pen C
Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
[TBL] [Abstract][Full Text] [Related]
10. Prescription drug prices: why do some pay more than others do?
Frank RG
Health Aff (Millwood); 2001; 20(2):115-28. PubMed ID: 11260933
[TBL] [Abstract][Full Text] [Related]
11. [The budget control function of the Drug Reimbursement System].
Pronk MH; Bonsel GJ; van der Kuy A
Ned Tijdschr Geneeskd; 2002 Sep; 146(37):1729-33. PubMed ID: 12357873
[TBL] [Abstract][Full Text] [Related]
12. The pricing of pharmaceuticals: an international comparison.
Dickson M
Clin Ther; 1992; 14(4):604-10; discussion 603. PubMed ID: 1525794
[TBL] [Abstract][Full Text] [Related]
13. Financing pharmaceuticals in transition economies.
Kanavos P
Croat Med J; 1999 Jun; 40(2):244-59. PubMed ID: 10234068
[TBL] [Abstract][Full Text] [Related]
14. Evaluating reference-based pricing: initial findings and prospects.
Narine L; Senathirajah M; Smith T
CMAJ; 1999 Aug; 161(3):286-8. PubMed ID: 10463052
[TBL] [Abstract][Full Text] [Related]
15. Recent public policies in The Netherlands to control pharmaceutical pricing and reimbursement.
Rigter H
Pharmacoeconomics; 1994; 6 Suppl 1():15-21. PubMed ID: 10155581
[TBL] [Abstract][Full Text] [Related]
16. Coverage of drug costs: reference-based pricing.
McGregor M
Can J Cardiol; 1998 May; 14(5):666-8. PubMed ID: 9627520
[TBL] [Abstract][Full Text] [Related]
17. The new pharmaceutical policy in Italy.
Fattore G; Jommi C
Health Policy; 1998 Oct; 46(1):21-41. PubMed ID: 10187653
[TBL] [Abstract][Full Text] [Related]
18. The piggyback dilemma.
Tanner DJ
Hosp Pharm; 1978 Jun; 13(6):326. PubMed ID: 10307644
[No Abstract] [Full Text] [Related]
19. A new entity for the negotiation of public procurement prices for patented medicines in Mexico.
Gómez-Dantés O; Wirtz VJ; Reich MR; Terrazas P; Ortiz M
Bull World Health Organ; 2012 Oct; 90(10):788-92. PubMed ID: 23109747
[TBL] [Abstract][Full Text] [Related]
20. The role of economic evaluation in the pricing and reimbursement of medicines.
Drummond M; Jönsson B; Rutten F
Health Policy; 1997 Jun; 40(3):199-215. PubMed ID: 10168752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
